Glycopyrrolate + Indacaterol Suppliers & Bulk Manufacturers
Available Forms: Inhalation powder delivered via Neohaler device/Breezhaler device
Available Strengths: Ultibro Breezhaler: Indacaterol 85 mcg + Glycopyrronium 43 mcg
Reference Brands: Utibron Neohaler(Dis.cntd in US-2020); Ultibro Breezhaler(EU)
Category: Respiratory Disorder
Glycopyrrolate + Indacaterol is available in Inhalation powder delivered via Neohaler device/Breezhaler device and strengths such as Ultibro Breezhaler: Indacaterol 85 mcg + Glycopyrronium 43 mcg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Glycopyrrolate + Indacaterol is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Glycopyrrolate + Indacaterol can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Glycopyrrolate + Indacaterol is a dual bronchodilator combination used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), while Indacaterol is a long-acting beta2-agonist (LABA). Together, they provide effective, once-daily bronchodilation, improving lung function and reducing COPD symptoms like breathlessness. Marketed under brand names such as Ultibro Breezhaler in the EU and previously as Utibron Neohaler in the US, this inhalation therapy offers enhanced respiratory relief. It is not intended for acute symptom relief but plays a vital role in COPD management by optimizing airflow and improving patients’ quality of life.
Frequently Asked Questions
Related Products
Fluticasone Furoate + Vilanterol
Strength:
92 mcg Fluticasone furoate / 22 mcg Vilanterol; 184 mcg Fluticasone furoate / 22 mcg Vilanterol
Form: Powder For Inhalation(DPI/MDI)
Reference Brands: Breo Ellipta®(US), Relvar Ellipta® (EU)
View Details
Mometasone + Formoterol
Strength:
100 mcg/5 mcg , 200 mcg/5 mcg
Form: Inhaler(MDI)
Reference Brands: Dulera®(US)
View Details
Ambroxol Hydrochloride
Strength:
Tab: 30 mg, 60 mg; Syrup: 15 mg/5 mL, 30 mg/5 mL; Drops: 7.5 mg/mL, 15 mg/mL
Form: Tablets, Syrup & Oral drops
Reference Brands: Mucosolvan®, Flavamed®, Ambrobeta®, Ambroxol-ratiopharm®(EU)
View Details
Carbocisteine
Strength:
Cap: 375 mg and 750 mg; Oral Solution: 50 mg/5 mL and 750 mg/5 mL
Form: Capsules, Oral Solutions/Syrups
Reference Brands: Mucodyne, Lisomucil®, Rhinathiol®, Muciclar®, Actithiol®, Mucolex®(US)
View DetailsQuick Response Guaranteed | Verified Suppliers
